by 
Bispecific antibodies are artificial proteins that can recognize and bind to two different epitopes or antigens simultaneously. These antibodies combine the binding domains of two different monoclonal antibodies into a single molecular construct, allowing them to redirect and bridge immune cells to targeted cancer cells. Bispecific antibodies have advantages over conventional monoclonal antibodies as they can target multiple antigens or receptors expressed on cancer or immune cells.
The Global Bispecific Antibodies Market is estimated to be valued at US$ 41.08 Mn in 2024 and is expected to exhibit a CAGR of 29% over the forecast period from 2023 to 2030.
Key Takeaways
Key players operating in the Bispecific Antibodies market are Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and F. Hoffmann-La Roche AG.
The rising prevalence of cancer and autoimmune diseases is fueling the demand for bispecific antibodies globally. In addition, the advantages of bispecifics over conventional monoclonal antibodies including dual targeting of cancer cells and improved specificity is further augmenting market growth. The key players are expanding their presence in high growth markets like Asia Pacific and Latin America to tap the widespread opportunities offered.
Market key trends
The bispecific antibodies market is witnessing increasing adoption of dual targeting therapeutic strategies. Bispecifics allow simultaneously blocking two different signals required for tumor growth and metastasis or linking T-cells to tumor cells. This enables enhanced specificity and efficacy. As a result, bispecific antibodies present potential treatment options even for aggressive cancers with high unmet needs. Many bispecific antibodies are in clinical trials for various cancer as well as autoimmune indications which once approved will strengthen the market dynamics in the coming years.
Porter’s Analysis
Threat of new entrants: High capital requirement for manufacturing facilities and R&D activities poses barriers.
Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power for pricing.
Bargaining power of suppliers: Suppliers of raw materials have lower bargaining power due to availability of substitutes.
Threat of new substitutes: Substitutes available but bispecific antibodies currently have advantages over other therapeutic modalities.
Competitive rivalry: Intense competition exists among major players to gain higher market share.
Geographical Regions
North America dominates the market and holds major share in terms of value due to presence of major players and advanced healthcare infrastructure for clinical trials.
Asia Pacific is expected to exhibit fastest growth during forecast period supported by rising healthcare spending, large patient pool, and growing focus of players to tap opportunities.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
